2023
DOI: 10.2139/ssrn.4361264
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/ Refractory Multiple Myeloma

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles